Gene Logic's Drug Repositioning Partnership (Phase R™ Program) begins upon our receipt of your failed, stalled or deprioritized drug candidates. The DRS Technology Platform is applied to each candidate, establishing new development paths by identifying potential alternative disease indications, clarifying ambiguous drug safety issues, and/or developing hypotheses to explain variable drug response. Alternative disease indications identified can be validated by Gene Logic using a mutually agreed upon gold-standard animal model. Upon successful validation, you may elect to restore the drug candidate back into clinical development.